Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award - PA: Drug Safety and Effectiveness

University of Ottawa

$105,000.00

A retrospective cohort study of the risk of adverse cardiovascular events following concomitant use of clopidogrel and proton pump inhibitors.

FY 2013-14

Summary
Clopidogrel is a commonly prescribed drug used to prevent the formation of blood clots in patients with heart disease. Physicians frequently prescribe proton pump inhibitors (PPIs), a stomach acid suppressor, to prevent bleeding in the stomach and intestines. The potential risks of taking clopidogrel and PPIs together is unclear, as recent studies have arrived at conflicting conclusions. Several studies suggest that PPIs reduce clopidogrel's antiplatelet action leading to a higher risk of heart attack, stroke, or death. The objective of this research project is to better understand the interaction between the two drugs. Specifically, this research will address the question: Do PPIs reduce the effectiveness of clopidogrel in preventing blood clots in patients with heart disease? To answer this question, electronic health records for a cohort of over 40 million patients from 300 contributing health care institutions in North America will be analysed. The risk of dying or having a heart attack or stroke in patients being treated with both drugs simultaneously will be assessed. The results of this study will have the advantage of being based on a much larger and more diverse patient population than in previous studies that have examined the use of both drugs in combination. With heart disease being a leading cause of hospitalization and death in many countries, the findings of this study regarding the interaction between PPIs and clopidogrel will be of importance to the large number of patients using these drugs, and will be of great value to clinicians in deciding on the most appropriate drug treatment regimen for heart disease patients.
Program
Doctoral Research Award - PA: Drug Safety and Effectiveness
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
296765
Name
Farhat Nawal
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Health systems / services
Prcname2
Doctoral Research Awards - B
Projecttitle
A retrospective cohort study of the risk of adverse cardiovascular events following concomitant use of clopidogrel and proton pump inhibitors.
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - PA: Drug Safety and Effectiveness
Keyworddelim
Adverse Drug Reactions; Cardiovascular Effects; Clopidogrel; Electronic Health Records; Patient Safety; Pharmacovigilance; Proton Pump Inhibitors; Regression Models; Retrospective Cohort Study; Secondary Health Databases
Abstract
Clopidogrel is a commonly prescribed drug used to prevent the formation of blood clots in patients with heart disease. Physicians frequently prescribe proton pump inhibitors (PPIs), a stomach acid suppressor, to prevent bleeding in the stomach and intestines. The potential risks of taking clopidogrel and PPIs together is unclear, as recent studies have arrived at conflicting conclusions. Several studies suggest that PPIs reduce clopidogrel's antiplatelet action leading to a higher risk of heart attack, stroke, or death. The objective of this research project is to better understand the interaction between the two drugs. Specifically, this research will address the question: Do PPIs reduce the effectiveness of clopidogrel in preventing blood clots in patients with heart disease? To answer this question, electronic health records for a cohort of over 40 million patients from 300 contributing health care institutions in North America will be analysed. The risk of dying or having a heart attack or stroke in patients being treated with both drugs simultaneously will be assessed. The results of this study will have the advantage of being based on a much larger and more diverse patient population than in previous studies that have examined the use of both drugs in combination. With heart disease being a leading cause of hospitalization and death in many countries, the findings of this study regarding the interaction between PPIs and clopidogrel will be of importance to the large number of patients using these drugs, and will be of great value to clinicians in deciding on the most appropriate drug treatment regimen for heart disease patients.
Competitiondate
201310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Farhat, Nawal
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
University of Ottawa - $105,000 Grant (2013-14) | Canada Spends